ATE380558T1 - Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten - Google Patents

Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten

Info

Publication number
ATE380558T1
ATE380558T1 AT02718052T AT02718052T ATE380558T1 AT E380558 T1 ATE380558 T1 AT E380558T1 AT 02718052 T AT02718052 T AT 02718052T AT 02718052 T AT02718052 T AT 02718052T AT E380558 T1 ATE380558 T1 AT E380558T1
Authority
AT
Austria
Prior art keywords
inhibitors
treat
heart disease
prevent heart
prevent
Prior art date
Application number
AT02718052T
Other languages
English (en)
Inventor
Charles Dinarello
Benjamin Pomerantz
Leonid Reznikov
Alden Harken
Yolande Chvatchko
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Application granted granted Critical
Publication of ATE380558T1 publication Critical patent/ATE380558T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02718052T 2001-01-29 2002-01-28 Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten ATE380558T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01101959 2001-01-29

Publications (1)

Publication Number Publication Date
ATE380558T1 true ATE380558T1 (de) 2007-12-15

Family

ID=8176323

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02718052T ATE380558T1 (de) 2001-01-29 2002-01-28 Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten

Country Status (32)

Country Link
US (1) US20040234523A1 (de)
EP (1) EP1355668B1 (de)
JP (2) JP4860897B2 (de)
KR (1) KR100857376B1 (de)
CN (1) CN1326562C (de)
AR (1) AR032422A1 (de)
AT (1) ATE380558T1 (de)
BG (1) BG66483B1 (de)
BR (1) BR0206819A (de)
CA (1) CA2435466C (de)
CY (1) CY1107203T1 (de)
CZ (1) CZ305653B6 (de)
DE (1) DE60224004T2 (de)
DK (1) DK1355668T3 (de)
EA (2) EA010180B1 (de)
EE (1) EE05534B1 (de)
ES (1) ES2295332T3 (de)
HK (1) HK1062810A1 (de)
HR (1) HRP20030609A2 (de)
HU (1) HU229164B1 (de)
IL (2) IL157024A0 (de)
ME (1) ME00549B (de)
MX (1) MXPA03006776A (de)
NO (1) NO331083B1 (de)
PL (1) PL213568B1 (de)
PT (1) PT1355668E (de)
RS (1) RS51125B (de)
SI (1) SI1355668T1 (de)
SK (1) SK287620B6 (de)
UA (1) UA80676C2 (de)
WO (1) WO2002060479A1 (de)
ZA (1) ZA200305439B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001236807A1 (en) 2000-02-10 2001-08-20 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
WO2002031115A2 (en) 2000-10-11 2002-04-18 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
JP5074030B2 (ja) 2003-05-13 2012-11-14 メルク セローノ ソシエテ アノニム Ｉｌ−１８結合タンパク質の活性変異体とその医学的応用
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP4961559B2 (ja) * 2004-03-11 2012-06-27 友昭 星野 インターロイキン１８阻害剤を有効成分とする疾患の予防又は治療剤
CA2609060C (en) 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
JP5091127B2 (ja) 2005-06-10 2012-12-05 アレス トレーディング ソシエテ アノニム Ｉｌ−１８結合タンパク質の精製のための方法
WO2009061832A1 (en) * 2007-11-05 2009-05-14 Kci Licensing Inc. Identification of tissue for debridement
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MX2016002719A (es) * 2013-09-05 2016-09-06 Ab2 Bio Sa Proteina de union a interleucina 18 (il-18bp) en enfermedades inflamatorias.
EP3265807A1 (de) 2015-03-05 2018-01-10 AB2 Bio SA Il-18-bindendes protein (il-18bp) und antikörper bei entzündungskrankheiten
WO2018013509A1 (en) * 2016-07-11 2018-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
ATE310528T1 (de) * 1996-09-12 2005-12-15 Idun Pharmaceuticals Inc Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
ATE346085T1 (de) * 1996-12-06 2006-12-15 Vertex Pharma Inhibitoren des interleukin-1-beta konvertierenden enzyms
KR20000076420A (ko) * 1997-03-18 2000-12-26 스타르크, 카르크 코르티코스테로이드에 대한 반응성을 조절하기 위한 방법 및 조성물
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE19743687C1 (de) * 1997-10-06 1998-11-26 Henkel Kgaa Detergensgemische und deren Verwendung
AU4961499A (en) * 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
EP1110969A4 (de) * 1998-09-01 2002-01-09 Hayashibara Biochem Lab Interleukin 18-bindende proteine
EP1022027A1 (de) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Antagonisten von Tumornecrosefaktor und ihre Verwendungen gegen Endometriose
EP1165490B1 (de) * 1999-03-16 2006-08-16 Cytovia, Inc. Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
ATE363465T1 (de) * 1999-04-09 2007-06-15 Cytovia Inc Caspase inhibitoren und ihre verwendung
WO2001003719A2 (en) * 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
AU2001236807A1 (en) * 2000-02-10 2001-08-20 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
DE60134009D1 (de) * 2000-05-05 2008-06-26 Inst Nat Sante Rech Med Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
UA80676C2 (en) 2007-10-25
IL157024A (en) 2014-02-27
KR20030070143A (ko) 2003-08-27
SK287620B6 (sk) 2011-04-05
EA200501549A1 (ru) 2006-04-28
ME00549B (me) 2011-10-10
MXPA03006776A (es) 2003-10-24
ZA200305439B (en) 2004-07-15
DE60224004D1 (de) 2008-01-24
HUP0303306A3 (en) 2005-12-28
BG108128A (bg) 2004-11-30
US20040234523A1 (en) 2004-11-25
AR032422A1 (es) 2003-11-05
EP1355668B1 (de) 2007-12-12
JP2009102354A (ja) 2009-05-14
HK1062810A1 (en) 2004-11-26
EA006767B1 (ru) 2006-04-28
IL157024A0 (en) 2004-02-08
HUP0303306A2 (hu) 2004-01-28
CN1499982A (zh) 2004-05-26
WO2002060479A1 (en) 2002-08-08
EP1355668A1 (de) 2003-10-29
SI1355668T1 (sl) 2008-06-30
SK10892003A3 (sk) 2004-02-03
BR0206819A (pt) 2004-02-03
CZ20032335A3 (en) 2004-07-14
CN1326562C (zh) 2007-07-18
PT1355668E (pt) 2008-01-04
EA200300844A1 (ru) 2003-12-25
CA2435466C (en) 2012-04-03
HRP20030609A2 (en) 2005-06-30
KR100857376B1 (ko) 2008-09-05
JP2004522748A (ja) 2004-07-29
BG66483B1 (bg) 2015-03-31
DK1355668T3 (da) 2008-05-05
NO20033228D0 (no) 2003-07-16
CA2435466A1 (en) 2002-08-08
ES2295332T3 (es) 2008-04-16
EA010180B1 (ru) 2008-06-30
HU229164B1 (en) 2013-09-30
RS51125B (sr) 2010-10-31
PL213568B1 (pl) 2013-03-29
JP4860897B2 (ja) 2012-01-25
NO331083B1 (no) 2011-10-03
DE60224004T2 (de) 2009-07-23
EE05534B1 (et) 2012-04-16
PL366802A1 (en) 2005-02-07
NO20033228L (no) 2003-09-26
CY1107203T1 (el) 2012-11-21
YU57803A (sh) 2006-05-25
CZ305653B6 (cs) 2016-01-27
EE200300328A (et) 2003-10-15

Similar Documents

Publication Publication Date Title
ATE414556T1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
ATE288748T1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
ATE452642T1 (de) Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
DE60327622D1 (de) Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien
ATE395075T1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE413385T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
ATE419856T1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE380558T1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
ATE526982T1 (de) Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen
DE60325353D1 (de) Behandlung von mukositis
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE60314003D1 (de) 4-(phenylpiperazinylmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen oder gastrointestinalen erkrankungen
DE60213234D1 (de) 4-(penylpiperidin-4-ylidenmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen, angstzuständen oder erkrankungen des magen-darm-trakts
ATE491442T1 (de) 1-phenyl-2- dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz
ATE418337T1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden
ATE465728T1 (de) Verwendung von endothelin antagonisten zur behandlung von knochenkrebs und damit verbundenen schmerzen
ATE404203T1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
ATE257384T1 (de) Verwendung von cilobradine oder pharmazeutisch akzeptablen salze zur behandlung oder prävention von herzversagen
ATE376416T1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
DE602004012770D1 (de) Saure chinolin-derivate und ihre verwendung zur prävention und/oder behandlung von erkrankungen im zusammenhang mit hyperglykämie
ATE359270T1 (de) Phenyl-piperidin-4-yliden-methyl-benzamidderiva e zur behandlung von schmerz oder magen-darm- erkrankungen
ATE345134T1 (de) Verwendung von indazol-derivaten zur behandlung von neuropathischen schmerzen
ATE228833T1 (de) Verwendung von 15-deoxyspergualin zur behandlung von hyperreaktiven entzündlichen erkrankungen und autoimmunerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1355668

Country of ref document: EP

EEFA Change of the company name